The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Relay Therapeutics Inc’s stock clocked out at $6.61, up 9.62% from its previous closing price of $6.03. In other words, the price has increased by $9.62 from its previous closing price. On the day, 1.36 million shares were traded. RLAY stock price reached its highest trading level at $6.62 during the session, while it also had its lowest trading level at $6.04.
Ratios:
To gain a deeper understanding of RLAY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 20.92 and its Current Ratio is at 20.92. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $4.
Jefferies Upgraded its Hold to Buy on September 10, 2024, whereas the target price for the stock was revised from $10.60 to $16.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 29 ’25 when Rahmer Peter sold 15,724 shares for $3.68 per share. The transaction valued at 57,864 led to the insider holds 377,998 shares of the business.
Rahmer Peter sold 1,359 shares of RLAY for $5,083 on Jul 28 ’25. The insider now owns 393,722 shares after completing the transaction at $3.74 per share. On Jul 29 ’25, another insider, Catinazzo Thomas, who serves as the Chief Financial Officer of the company, sold 18,380 shares for $3.68 each. As a result, the insider received 67,638 and left with 335,295 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 1139639424 and an Enterprise Value of 517047424. For the stock, the TTM Price-to-Sale (P/S) ratio is 136.32 while its Price-to-Book (P/B) ratio in mrq is 1.70. Its current Enterprise Value per Revenue stands at 61.885 whereas that against EBITDA is -1.54.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.70, which has changed by -0.09186745 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $7.00, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is 50.67%, while the 200-Day Moving Average is calculated to be 78.18%.
Shares Statistics:
It appears that RLAY traded 1.98M shares on average per day over the past three months and 1610240 shares per day over the past ten days. A total of 171.69M shares are outstanding, with a floating share count of 130.15M. Insiders hold about 24.51% of the company’s shares, while institutions hold 78.59% stake in the company. Shares short for RLAY as of 1759190400 were 22643430 with a Short Ratio of 11.45, compared to 1756425600 on 22729030. Therefore, it implies a Short% of Shares Outstanding of 22643430 and a Short% of Float of 15.93.
